When beryllium exposure cessation fails to achieve improvement in pulmonary function
Clinical scenario
In chronic beryllium disease (CBD), the first-line approach is removal of the patient from further beryllium exposure. For patients in early disease without physiological impairment, this is combined with periodic re-evaluation every one to two years, with no corticosteroid therapy initiated at that stage. This protocol applies when that first-line strategy does not achieve the expected improvement in pulmonary function.
First-line failure condition
The prior treatment — cessation of beryllium exposure — did not achieve improvement in pulmonary function. This is the defined trigger for escalation to the structured regimen described in the full protocol.
Next-line approach (partial overview)
When beryllium removal alone is insufficient, the evidence-based next step involves a course of oral corticosteroid therapy. The full protocol defines the complete regimen and specifies the measurable therapeutic targets: improvement in forced vital capacity, diffusing capacity for carbon monoxide (DLCO), and the active lesion score on high-resolution CT of the chest.
References
DOI: 10.1080/15459620903158698
- Dosages and regimens of corticosteroids vary, but common recommendations suggest initiating therapy with oral prednisone, from 20 to 40 mg/d (or every other day).
- Generally, patients are treated for 3 to 6 months followed by a gradual taper to the lowest effective dose.
- A 2008 study by Marchand-Adam also showed a short-term improvement in lung function with oral corticosteroids in eight patients with a 4–12 month follow-up.
- They demonstrated a significant improvement in the active lesion score in all patients; active lesions were defined as ground glass opacities, micronodules, nodules, and alveolar consolidations.
View source ↗